Temozolomide Update
Braintumor Website

Cerebrospinal Fluid Levels of Temozolomide as a Surrogate Marker for Brain Penetration.
Roger Stupp, Sandrine Ostermann, Serge Leyvraz, Chantal Csajka, Thierry Buclin, Laurent A Decosterd, University Hospital CHUV, Lausanne, Switzerland.

Presented at the American Society Of Clinical Oncology, 2001 Conference

Background: The poor clinical responses observed with many chemotherapy agents against brain tumors may be due to their restricted passage through the blood-brain barrier, resulting in insufficient levels at the tumor site. Cerebro-spinal fluid (CSF)-concentrations of a drug may give an estimation on its capacity to penetrate into the brain. Temozolomide (TMZ), a novel oral chemotherapy agent has been recently approved for malignant glioma. However, only little is known on drug penetration into the brain and CSF in humans.
Methods: TMZ concentrations were measured in CSF and plasma from patients enrolled in 2 clinical studies wherein patients with newly diagnosed or recurrent glioma were to receive either TMZ at a daily dose of 75mg/m2 and concomitant radiation [Stupp et al: PASCO 2000, abstract #632], or standard 200 mg/m2 daily x 5. A single CSF sample and 3 blood samples were taken at selected times between 1.5-6h after TMZ intake. Samples were immediately acidified for insuring TMZ stabilization and analyzed by high-performance liquid chromatography [Shen F et al: J Chromatog B 665:291, 1995]. Results: A total of 310 plasma and 58 CSF samples were collected from 33 patients, including 2 patients with multiple consecutive CSF-samples collected through an Ommaya-reservoir. Since TMZ has linear pharmacokinetics, all data were calculated after normalizing drug levels to a 200 mg/m2 dose. The TMZ CSF/plasma ratio progressively increases up to 40% until 4 hours after drug intake, time at which an equilibrium is reached.
Conclusions: These data indicate that TMZ readily crosses the blood-brain barrier. Population-based pharmacokinetic evaluation is ongoing. These values may allow future comparison with other potentially active agents for brain tumors. (supported in part by Schering-Plough Research Institute)
TMZ plasma & CSF concentrations

TMZ-dose (mg/m2)

n (samples)

Plasma (µg/ml)

CSF (µg/ml)

Mean ratio in %

75

21

0.13-2.45

0.0-0.77

24.8 ± 16.0

200

33

1.11-8.20

0.16-1.93

32.2 ±12.9

All

54

   

29.4 ±15.0

at equilibrium (after approx. 4 h)

22

   

39.7 ±11.4




Home | Brain Tumor Guide | Search | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure NovoTTF-100A | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us | Doctors Address Book



Copyright (c) 1993 - 2014 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites